Lupin Eyes 20% Growth Rate In U.S. From 110 Applications To FDA
This article was originally published in PharmAsia News
Executive Summary
Lupin is aiming for a 20% growth rate in the U.S. market, relying on approvals of many of the 110 drugs it has filed for approval by the FDA within the next four years, according to S Ramesh, President and CFO.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.